The group wants Congress to step in and pass legislation that could curb so-called “copycat” THC products, which are particularly appealing to kids.
During the SAMHSA Drug Testing Advisory Board meeting, officials discussed emerging trends with cannabis-derived isomers.
The FDA still has more questions than answers on CBD, but it is making strides on conducting the research and collecting the data needed to release product regulations.
The meeting, which will use cannabinoids as a “case study” in assessing the “safety” of certain foods and supplements, comes as the FDA wrestles with rulemaking for CBD products.
While cannabidiol products aren’t yet FDA approved for humans or animals, that hasn’t stopped plenty of sellers from marketing their products to treat, for example, animals’ anxiety.
A two-day event hosted by the Food and Drug Law Institute highlighted cannabis regulatory headaches, including delta-8 THC and a lack of uniformity in lab testing.
The U.S. Food and Drug Administration has been working for years on rules for products containing cannabis-derived compounds like CBD. But nothing has yet materialized.
The research comes amid a broader agency effort to collect data on cannabinoids, which will help shape forthcoming rules on approved products.
The 2018 Farm Bill legalized hemp, and, by extension, hemp-derived CBD, but the Food and Drug Administration has not yet released rules to guide the growing industry.
The Food and Drug Administration has said for years that it is working on rules for cannabinoid-containing products. But it has also said that crucial research and data are lacking.
The federal law on cannabis has remained unchanged for more than half a century. Yet as states race toward legalization, federal agencies have begun to play catch up.
A policy coordinator with the FDA’s Cannabis Product Committee spoke about CBD during a Food and Drug Law Institute event focused on cannabis.
The Food and Drug Administration has been on a march to collect cannabinoid-related data. The “Cannabis-Derived Products Data Acceleration Plan” released this month is its most robust effort.
Epidiolex strikes again: the FDA-approved CBD-based pharmaceutical is complicating other uses of CBD.
CSU Pueblo hosted a pharmacist at Greenwich Biosciences to talk about the company’s path with Epidiolex, a CBD-based medicine extracted from cannabis plants.
The group, which includes Coca-Cola and Kellogg’s as members, says its membership is “CBD curious” but that the lack of federal regulation is keeping major brands at bay.